吉西他滨加顺铂治疗复发性卵巢癌的临床观察  

Clinical observation of gemcitabine plus cisplatin in treatment of recurrent ovarian cancer

作　　者：李亭山[1] 贾锋[1] 侯美英[1] 孙雷[1] 刘元建[1] 

机构地区：[1]济宁医学院附属金乡医院,山东金乡272200

出　　处：《现代肿瘤医学》2010年第8期1623-1625,共3页Journal of Modern Oncology

摘　　要：目的:探讨复发性卵巢癌治疗方法,评估吉西他滨联合顺铂治疗复发性卵巢癌的疗效及不良反应。方法:56例复发性卵巢癌,用吉西他滨1000mg/m2,第1、8天,顺铂35mg/m2,第1、8天静滴,21天为1周期。结果:56例患者总有效率60.7%,其中CR10例(17.9%),PR24例(42.9%)。中位疾病进展时间5.5个月(2.5-20个月),中位生存期12.5个月。其中32例铂类耐药和24例铂类敏感患者的有效率、中位生存期分别为56.3%和66.7%(P=0.95)、10.5和14.5个月(P=0.003)。不良反应主要是白细胞减少和血小板减少。结论:吉西他滨加顺铂是治疗复发性卵巢癌的有效方案,不仅可用于铂类敏感患者,也可用于铂类耐药患者,其不良反应可以接受。Objective： To evaluate the efficacy and toxicities of gemcitabine plus cisplatin for patients with relapsed ovarian cancer. Methods： Fifty-six patients with recurrent ovarian carcinoma received gemcitabine （1000 mg/m2 ） plus cisplatin （35 mg/ m2 ） on days 1 and 8, 21days as one cycle. Results： Of 56 patients,there were 10 （17.9%） complete and 24 （42.9%） partial responses,overall response rate was 60.7%. The median time to progression was 5.5 months with a range of 2.5 to 20 months. Median overall survival for all 56 patients was 12.5 months. Among 32 platinum-resistant patients,response rate was 56.3% median survival time was 10.5 months. Among 24 platinum-sensitive patients, response rate was 66.7%,median survival time was 14.5 months. There were leukopenia grade Ⅲ in 35.7% ,grade Ⅳ in17.9%; thrombocytopenia grade Ⅲ in 28.6 % ,grade Ⅳ in 14. 3% of patients. Conclusion： Cisplatin plus gemcitabine is active in patients with relapsed ovarian cancer. The adverse effects are tolerable.

关 键 词：卵巢肿瘤 肿瘤复发 吉西他滨 顺铂 

分 类 号：R737.31[医药卫生—肿瘤]